118 related articles for article (PubMed ID: 36449565)
1. Trabectedin impairs invasiveness and metastasis in adrenocortical carcinoma preclinical models.
Abate A; Tamburello M; Rossini E; Basnet RM; Ribaudo G; Gianoncelli A; Hantel C; Cosentini D; Laganà M; Grisanti S; Tiberio GAM; Memo M; Berruti A; Sigala S
Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36449565
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines.
Tamburello M; Abate A; Rossini E; Basnet RM; Zizioli D; Cosentini D; Hantel C; Laganà M; Tiberio GAM; Grisanti S; Memo M; Berruti A; Sigala S
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047801
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells.
Abate A; Rossini E; Bonini SA; Fragni M; Cosentini D; Tiberio GAM; Benetti D; Hantel C; Laganà M; Grisanti S; Terzolo M; Memo M; Berruti A; Sigala S
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32283844
[TBL] [Abstract][Full Text] [Related]
4. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
5. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
6. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C
Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961
[TBL] [Abstract][Full Text] [Related]
7. A 3D adrenocortical carcinoma tumor platform for preclinical modeling of drug response and matrix metalloproteinase activity.
Dedhia PH; Sivakumar H; Rodriguez MA; Nairon KG; Zent JM; Zheng X; Jones K; Popova LV; Leight JL; Skardal A
Sci Rep; 2023 Sep; 13(1):15508. PubMed ID: 37726363
[TBL] [Abstract][Full Text] [Related]
8. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
9. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
[TBL] [Abstract][Full Text] [Related]
10. Development of new preclinical models to advance adrenocortical carcinoma research.
Kiseljak-Vassiliades K; Zhang Y; Bagby SM; Kar A; Pozdeyev N; Xu M; Gowan K; Sharma V; Raeburn CD; Albuja-Cruz M; Jones KL; Fishbein L; Schweppe RE; Somerset H; Pitts TM; Leong S; Wierman ME
Endocr Relat Cancer; 2018 Apr; 25(4):437-451. PubMed ID: 29371329
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
[TBL] [Abstract][Full Text] [Related]
12. In vitro antitumor activity of progesterone in human adrenocortical carcinoma.
Fragni M; Fiorentini C; Rossini E; Fisogni S; Vezzoli S; Bonini SA; Dalmiglio C; Grisanti S; Tiberio GAM; Claps M; Cosentini D; Salvi V; Bosisio D; Terzolo M; Missale C; Facchetti F; Memo M; Berruti A; Sigala S
Endocrine; 2019 Mar; 63(3):592-601. PubMed ID: 30367443
[TBL] [Abstract][Full Text] [Related]
13. MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.
Creemers SG; van Koetsveld PM; De Herder WW; Dogan F; Franssen GJH; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Mar; 26(3):367-378. PubMed ID: 30650062
[TBL] [Abstract][Full Text] [Related]
14. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
15. FSCN1 as a new druggable target in adrenocortical carcinoma.
Ruggiero C; Tamburello M; Rossini E; Zini S; Durand N; Cantini G; Cioppi F; Hantel C; Kiseljak-Vassiliades K; Wierman ME; Landwehr LS; Weigand I; Kurlbaum M; Zizioli D; Turtoi A; Yang S; Berruti A; Luconi M; Sigala S; Lalli E
Int J Cancer; 2023 Jul; 153(1):210-223. PubMed ID: 36971100
[TBL] [Abstract][Full Text] [Related]
16. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
[TBL] [Abstract][Full Text] [Related]
17. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.
Fiorentini C; Fragni M; Perego P; Vezzoli S; Bonini SA; Tortoreto M; Galli D; Claps M; Tiberio GA; Terzolo M; Missale C; Memo M; Procopio G; Zaffaroni N; Berruti A; Sigala S
J Clin Endocrinol Metab; 2016 Dec; 101(12):4594-4602. PubMed ID: 27626976
[TBL] [Abstract][Full Text] [Related]
18. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
[TBL] [Abstract][Full Text] [Related]
19. Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.
Demeure MJ; Stephan E; Sinari S; Mount D; Gately S; Gonzales P; Hostetter G; Komorowski R; Kiefer J; Grant CS; Han H; Von Hoff DD; Bussey KJ
Ann Surg; 2012 Jan; 255(1):140-6. PubMed ID: 22156929
[TBL] [Abstract][Full Text] [Related]
20. The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.
Pezzani R; Rubin B; Bertazza L; Redaelli M; Barollo S; Monticelli H; Baldini E; Mian C; Mucignat C; Scaroni C; Mantero F; Ulisse S; Iacobone M; Boscaro M
Invest New Drugs; 2016 Oct; 34(5):531-40. PubMed ID: 27177645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]